NCT06120881RecruitingEarly phase 1
Precision Dosing of Metformin in Youth With T2D
Pilot Study of Precision Dosing of Metformin in Youth With Type 2 Diabetes (PRECISE_T2D)
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 1 Nov 2023
- Start date
- 25 Apr 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of California, San Francisco
- Diseases
- Type 2 diabetes
- NCT number
- NCT06120881
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From 25 Apr 2024 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known history of ongoing renal or hepatic disease.
- Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently.
Other
- Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8).
Who the study is looking for
- Age 10-21 years
- Provider diagnosis of T2D
- Stable medication regimen for 2 weeks before screening visit (No addition or removal of medications and no more than 20% change in insulin dose)
- ≥ 1 month from T2D diagnosis
- Taking regular metformin (not extended-release formula)
- Ability to wear CGM for a total of 6 weeks while in the study.
- English or Spanish speakers.
- Willing to abide by recommendations and study procedures.
- Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF.
- Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Age in the registry: 10 years to 21 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes Clinic Coordinator of this site? Confirm its status | Oakland | United States | Recruiting |
| UCSF Benioff Children's Hospital San Francisco, Madison Clinic for Pediatric Diabetes Coordinator of this site? Confirm its status | San Francisco | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.